|
| |
Parkin & Synuclein (alpha, beta,
and gamma) Antibodies
Parkinson's disease (PD)
is a common neurodegenerative disorder with a lifetime incidence of
approximately 2 percent; the clinical manifestations of this neurodegenerative
disorder include resting tremor, muscular rigidity, bradykinesia, and postural
instability. A relatively specific pathological feature accompanying the
neuronal degeneration is an intracytoplasmic inclusion body, known as the
Lewy body. A mutation was identified in the alpha
synuclein gene, which codes for a presynaptic protein thought to be involved in
neuronal plasticity, this mutation may cause a conformational change that
renders alpha-synuclein more prone to self aggregation and deposition in Lewy
bodies, which finally leads to oxidative stress and misfolding of
alpha-synuclein.
Parkin gene, mutations in this gene are reported
in early autosomal-recessive form of PD, however these mutations do not
degenerate Lewy bodies. The Parkin gene product (Parkin)
is involved in protein degradation as a ubiquitin protein ligase, the known
substrates of Parkin include PAEL-R (Parkin-associated endothelin receptor-like
receptor), Ubiquitination of Pael-R by Parkin leads to its degradation in the
proteasome, however failure to ubiquitinate it leads to death of neuron.
Parkin is a 465aa
protein in human (chr 6q25.2-q27) and mouse, expressed in many tissues,
including brain, heart, testis, and skeletal muscle. In the brain, Parkin is
expressed in various regions including substantia nigra.
Alzheimer's Disease (AD)
is another neurodegenerative disorder characterized by progressive loss of
memory and cognition in the elderly, One of the most important and initial step
involves proteolytic cleavage of amyloid precursor protein releasing short 40,
42 & 43 aa peptides, the deposits of these short peptides has been found to
contain anti-chymotrypsin (ACT), Apolipoprotein (Apo-E)
and two additional proteins named alpha-synuclein and beta-synuclein.
The synuclein exists in 3 isoform
alpha-syn (chrm 4q21), a 140aa protein, implicated
in pathogenesis of PD and related neurodegenerative disorders, it is mainly
expressed in brain specifically in neuronal cell bodies and synapses. The 134 aa
beta-syn (chrm 5q35) is homologous to 14 kDa bovine
phosphoneuroprotein 14; SCNB has shown to be highly expressed in the substantia
nigra of the brain. Recently a new isoform termed
gamma-synuclein (SNCG) or breast cancer gene 1 (BCG1) has been cloned
(human 127 aa (chrm 10q23), rat/mouse 123 aa). Higher levels of expression of
SNCG have been reported in advanced breast carcinomas. All three synuclein show
~40% identity.
Publications on Parkin and
Synuclein-alpha using ADI's Antibodies:
Parkin, Hase A et al 2002 Brain Res. 930, 143-149
Characterization of parkin in bovine peripheral nerve.
Synuclein-alpha, Sudo S et al 2002 Acta
Neuropathologica DOI 10.1007 Motor neuron disease with dementia combined with
degeneration of striatonigral and pallidoluysian systems.
|
Items |
Antigen peptide location |
Antibody Host |
Expected Ab Crossreactivity * |
Aff. Pure IgG/Mab
Cat #
100 ug |
* Control Peptide Cat#
100 ug |
|
Parkin (Ab # 1) |
H, 23 aa, CT |
Rb |
m, r, h |
PARK11-A |
PARK11-P |
Parkin isoform 2
(Ab # 2) |
Prakin
isoform 2
Protein |
G, poly |
H
|
PARK12-A |
|
|
a-synuclein (Ab #1) |
H, 16 aa |
Rb |
m, r, h |
SYN11-A |
SYN11-P |
|
a-synuclein (Ab #2) |
R, 19 aa |
Rb |
r, m |
SYN12-A |
SYN12-A |
|
a-synuclein
(Ab #3)
|
Human
alpha Syn protein |
m, mono |
H (m,
r?) |
SYN16-M
|
|
|
a-synuclein (P#1) |
H, alp-syn |
Human Alpha-Synuclein, Purified Recombinant Protein Cat # SYN-25R (50 ug)
W.blot +ve protein control SYN11-C(100ul) |
|
a-synuclein (P#2) |
H, alp-syn |
Human Alpha-Synuclein, Purified Recombinant Protein Cat # SYN-A30P-R (50 ug) |
|
a-synuclein (P#3) |
H, alp-syn |
Human Alpha-Synuclein, Purified Recombinant Protein Cat # SYN-A53T-R (50 ug) |
|
a-synuclein
(Protein #3) |
H, alp-syn, mutant A53T |
Alpha-Synuclein, Purified Recombinant Protein Cat # SYN-A53T-R (50 ug) |
|
a-synuclein
(Protein # 4) |
H, alp-syn mutant A30P/A53T |
Alpha-Synuclein, Recombinant double mutant Protein Cat # SA3053T-R (50ug) |
|
a-synuclein
(Protein # 5) |
H, alp-syn deletion mutant (61-95) |
Alpha-Synuclein, Recombinant deletion mutant Protein Cat # SD6195-R (25ug) |
|
a-synuclein
(Protein # 6) |
H, alp-syn deletion mutant (61-140) |
Alpha-Synuclein, Recombinant deletion mutant Protein Cat # SD61140-R (25ug) |
|
a-synuclein
(Protein # 7) |
H, alp-syn deletion mutant (96-140) |
Alpha-Synuclein, Recombinant deletion mutant Protein Cat # SD96140-R (25ug) |
|
b-synuclein (Ab #1) |
H, 14 aa |
Rb |
m, h, r |
SYN13-A |
SYN13-P |
|
b-synuclein
(Protein #1) |
H, beta-syn |
Beta-Synuclein, Recombinant protein (134aa) Cat # SYN-25R (50 ug)
Beta-Synuclein, W.blot +ve protein control SYN13-C (100 ul) |
|
g-synuclein (Ab #1) |
M, 18 aa CT |
Rb |
r, m |
SYN14-A |
SYN14-P |
|
g-synuclein (Ab #2) |
H, 17 aa CT |
Rb |
h |
SYN15-A |
SYN15-P |
|
g-synuclein (P#1) |
H, g-syn |
Human Gamma-Synuclein, Purified Recombinant Protein Cat # SYN-35R (50 ug)
W.blot +ve protein control SYN15-C(100ul) |
m=mouse; r=rat; h=human; b=bovine; d=dog; ~CT or ~NT=near C or N-terminus.
EC=Extracellular; CP=Cytoplasmic domain;
* Expected antibody crossreactivity
information is mostly based upon high (>70%) sequence conservation of
antigenic/control peptides in various species. When antibody crossreactivity has
actually been experimentally confirmed in various species, it will be mentioned
in the appropriate data sheets.
"Neat Antisera or antisera" are the unpurified antiserum and it is suitable for
ELISA and Western.
"Affinity pure" IgG may be more suitable for immunohistochemical (IHC)
applications and to reduce background in most immunological applications
including ELISA and Western.
"Control peptides" can not be used for Western as they are very short peptides.
They are intended for ELISA or antibody blocking studies to establish antibody
specificity.
Western blot +ve protein controls, where available, are semi-pure, pure or
recombinant proteins that are formulated in SDS-PAGE sample buffer (reduced).
They are recommended to be used for Western (load 10 ul/lane) for visualization
with antibodies.
All Products are for in vitro research use only.
|